Assembly Biosciences (ASMB) Non-Current Deferred Tax Liability (2014 - 2021)

Assembly Biosciences' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $2.5 million for Q3 2021.

• On a quarterly basis, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $2.5 million in Q3 2021; TTM through Sep 2021 was $2.5 million, a 0.0% change from a year earlier, with the FY2020 full-year figure at $2.5 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability held at $2.5 million in Q3 2021 per ASMB's latest filing, from $2.5 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $3.3 million in Q4 2018 and bottomed at $2.1 million in Q4 2017.
• The 5-year median for Non-Current Deferred Tax Liability is $2.5 million (2019), against an average of $2.7 million.
• Across the five-year window, Non-Current Deferred Tax Liability slumped 80.79% in 2017 and jumped 52.25% in 2018, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $2.1 million in 2017, then soared by 52.25% to $3.3 million in 2018, then decreased by 22.17% to $2.5 million in 2019, then changed by 0.0% to $2.5 million in 2020, then changed by 0.0% to $2.5 million in 2021.
• Per Business Quant, the three latest ASMB Non-Current Deferred Tax Liability figures stand at $2.5 million (Q3 2021), $2.5 million (Q2 2021), and $2.5 million (Q1 2021).